An alveolar macrophage-targeted ciprofloxacin polymeric prodrug improves survival in a murine model of Klebsiella pneumoniae pneumonia
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.00363-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Ciana L López und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Ciprofloxacin, Klebsiella pneumoniae, Macrophages, Alveolar, Klebsiella Infections. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Science Foundation Graduate Research Fellowship Program.
Abstract (Originalsprache)
Klebsiella pneumoniae is a leading cause of both hospital- and community-acquired pneumonia. Nanomaterials have the potential to deliver antibiotics directly to sites of infection with improved pharmacokinetics and to avoid development of antimicrobial resistance. We previously demonstrated the use of alveolar macrophage (AM)-targeted polymeric prodrugs to prevent pneumonia in murine models caused by the facultative intracellular pathogens Francisella novicida and Burkholderia pseudomallei . These fully synthetic mannose-tagged polymers engage with AM mannose receptors, permitting uptake and triggering intracellular ciprofloxacin release. Here we show that the AMs can also serve as a reservoir for releasing antibiotics to treat infections caused by a primarily extracellular bacterium. Aerosolized ciprofloxacin polymeric prodrugs significantly improved survival in a murine model of K. pneumoniae pneumonia, reduced lung bacterial burden, lessened extent of lung injury, and prevented excessive neutrophilic inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, University of Washington, Seattle, Washington, USA.
- Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA.
- Department of Comparative Medicine, University of Washington, Seattle, Washington, USA.
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
- Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Ciana L López, Sarah M Baker, T Eoin West, Shawn J Skerrett, Patrick S Stayton
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Science Foundation Graduate Research Fellowship Program
Zitieren
APA
López, C. L., Rerolle, G., Snyder, S., Arias, O., Bashmail, A., Gonzalez, G., Roy, D., Lee, B., Snyder, J. M., Doorn, I., Baker, S. M., Wright, S. W., West, T. E., Skerrett, S. J., & Stayton, P. S. (2026). An alveolar macrophage-targeted ciprofloxacin polymeric prodrug improves survival in a murine model of Klebsiella pneumoniae pneumonia. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00363-25
Vancouver
López CL, Rerolle G, Snyder S, Arias O, Bashmail A, Gonzalez G, et al. An alveolar macrophage-targeted ciprofloxacin polymeric prodrug improves survival in a murine model of Klebsiella pneumoniae pneumonia. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00363-25
BibTeX
@article{Lpez2026,
author = {López, Ciana L and Rerolle, Guilhem and Snyder, Sarah and Arias, Osvaldo and Bashmail, Abdullah and Gonzalez, Giovany and Roy, Debashish and Lee, Brian and Snyder, Jessica M and Doorn, Isabella and Baker, Sarah M and Wright, Shelton W and West, T Eoin and Skerrett, Shawn J and Stayton, Patrick S},
title = {An alveolar macrophage-targeted ciprofloxacin polymeric prodrug improves survival in a murine model of Klebsiella pneumoniae pneumonia},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00363-25}
}
EUVIMED